Molecule News and Research

RSS

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

Researchers identify FMRP protein as key player in RNA editing

The most common form of heritable cognitive impairment is Fragile X Syndrome, caused by mutation or malfunction of the FMR1 gene. Loss of FMR1 function is also the most common genetic cause of autism. Understanding how this gene works is vital to finding new treatments to help Fragile X patients and others.

31 Oct 2011

Research focuses on JQ1 molecule that tricks NUT midline carcinoma cancer cells

NUT midline carcinoma (NMC) is a cancer without a cure, and one that affects all age groups. NMC is a rapid-growth disease with an average survival time of four and a half months after diagnosis, making the development of clinical trials for potential therapies or cures for this cancer difficult, to say the least.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

Scientists describe how protein acts as courier in cell signaling pathways

Normal development, from fertilized egg to adult organism, depends on each cell receiving proper instructions from its environment. In response to such incoming information, receptors on a cell's surface send signals to the nucleus that tweak gene expression and control cellular function.

28 Oct 2011

Patients with ANCA-associated vasculitis harbor Flt1 protein that blocks blood vessel repair

In some kidney diseases, patients have high blood levels of a protein that blocks blood vessel repair, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011

Functional link between IKBKE and Akt activation in breast cancer

Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.

28 Oct 2011

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

NCI awards UAB $2.3M brain-tumor SPORE grant

The UAB Comprehensive Cancer Center and the UAB Division of Neurosurgery have been awarded a prestigious SPORE, or Specialized Program of Research Excellence, grant from the National Cancer Institute for $2.3 million over three years to conduct research and develop new therapies to treat brain tumors.

28 Oct 2011

Inhibition of protein kinase B suppresses IKBKE's oncogenic transformation

28 Oct 2011

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Phase 1 clinical studies of the experimental anticancer drug lenvatinib indicate that it may achieve at least a partial response in thyroid, endometrial, and renal cancers and melanoma.

28 Oct 2011

Microglia plays a key role in memory and learning

Immune system cells of the brain, which scavenge pathogens and damaged neurons, are also key players in memory and learning, according to new research by Duke neuroscientists.

27 Oct 2011

U of A researchers discover potential new drug target for MS

Medical researchers at the University of Alberta have discovered a potential new drug target for Multiple Sclerosis that could prevent physical disability associated with the disease, once a new drug is developed.

27 Oct 2011

NCI awards Metabolomx SBIR contract to develop sensor array system for detecting lung cancer

Metabolomx, a diagnostic company focused on breath analysis for the detection of cancer, today announced the Company was awarded a Small Business Innovation Research (SBIR) contract by the National Cancer Institute (NCI). The $1.14 million combined Phase I/II Fast-Track contract will support the research and development of Metabolomx' sensor array system to detect lung cancer.

24 Oct 2011

Comprehensive ADMESeq Research Screening Panel launched

RainDance Technologies, Inc., the Digital Biology Company, and Ambry Genetics, today announced the launch of a comprehensive targeted sequencing panel to screen genes involved with drug absorption, distribution, metabolism, and excretion (ADME) research. The ADMESeq Research Screening Panel enables researchers to simultaneously interrogate 242 known pharmacogenetic genes using next-generation sequencing (NGS) systems.

24 Oct 2011

Small molecule selectively blocks gene activity regulated by thyroid hormone

A small molecule developed at St. Jude Children's Research Hospital advances progress toward more tailored drugs in research that also offers insight into the biology of thyroid hormone.

22 Oct 2011

MRI helps researchers to study molecules directly in organs and tissue

Researchers at Lund University can now study molecules which are normally only found in very small concentrations, directly in organs and tissue. After several years of work, researchers in Lund have managed to construct an instrument that 'hyperpolarises' the molecules and thus makes it possible to track them using MRI.

22 Oct 2011

Researchers identify cancer cell cycle-regulated mechanism

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have identified a cell cycle-regulated mechanism behind the transformation of normal cells into cancerous cells.

22 Oct 2011